Trial Profile

A Phase II Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jul 2020 Status changed from active, no longer recruiting to discontinued due to the changing efficacy of treatments for metastatic urothelial cancer
04 Jun 2019 Results assessing Correlation of methylthioadenosine phosphorylase (MTAP) loss with response to pemetrexed presented at the 55th Annual Meeting of the American Society of Clinical Oncology
22 May 2019 According to ClinicalTrials.gov, change has been noticed in trial design; treatment arms has been changed from parallel assignment to single group assignment and there will be no cohorts. Folic acid, vitamin B12, and dexamethasone has been removed from treatment table.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com